Navigation Links
Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I
Date:10/2/2008

PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain.

Neuropathic pain is a major chronic pain condition, with an estimated prevalence in the world's population of up to 6%, according to the most recent surveys, with many causes such as shingles, herpes, diabetes, antiviral or antitumor chemotherapy surgery, or low back disorders. Neuropathic pain does not respond well to usual painkillers. Worldwide market for neuropathic pain is estimated to reach 5 billion USD by 2010.

This compound originates from the work of Pharmaleads' chief scientists, Professors Bernard P. Roques and Marie-Claude Fournie-Zaluski, and is a dual inhibitor of both enzymes responsible for the rapid degradation of enkephalins, the endogenous opiates. It therefore elicits an analgesic effect wherever enkephalins are produced as a response to a painful stimulus, and maintains a high level of these natural analgesic substances by preventing their rapid degradation.

According to Thierry Bourbie, Chairman and CEO of Pharmaleads, "PL37 is Pharmaleads' first compound to enter clinical development and the first representative of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug development company. Neuropathic pain remains poorly treated and there is an urgent need to develop and bring to patients and doctors a specific oral treatment that would be really active and well tolerated. This looks very promising."

Bernard P. Roques, Vice-President and CSO of Pharmaleads explains: "The inhibition of both enzymes, responsible for the inactivation, in the body, of naturally present opiates, enhances their analgesic properties. PL37 physiological action in all areas where pain is present leads to very promising prope
'/>"/>

SOURCE Pharmaleads
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related medicine technology :

1. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
4. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
5. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
8. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
9. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
10. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)..., THOUSAND OAKS, Calif., Dec. 3 /PRNewswire-Fir...udents from across the United States (U.S.) and Eu...gain hands-on laboratory experience under renowned...es. Now, the Amgen Scholars - past, present and f...mgen Scholars Community at www.amgenscholars.com ...
(Date:12/3/2009)... , PISCATAWAY, N.J., Dec. 3 /PRNewswire-FirstC...ard: MLSS), the recognized leader in advanced inje...tered into a joint venture with China National Med...chang Humanwell Pharmaceutical Co. Ltd., both inco...RC"), to develop orthopedic and epidural drug deli...
(Date:12/3/2009)... , WALTHAM, Mass., Dec. 3 D...arch and advisory firms focusing on pharmaceutical...diabetes drug market in Brazil will grow from $417...ected 15 percent annual growth rate is attributed ..., increased use of new generation antidiabetics su...
Breaking Medicine Technology:New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 2New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 3Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 2Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 3Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3A new scan for lung diseases 59354 1A new scan for lung diseases 59354 2Blood vessel builders 10333 1Blood vessel builders 10333 2Dogs Helping to Advance Cancer Research 59351 1Dogs Helping to Advance Cancer Research 59351 2
...ciences From University of Cambridge -...MBRIDGE, England, Oct. 24 Stem Cell Sciences plc,...mmercialisation of stem,cells and stem cell techno...for reprogramming adult mammalian cells into authe... published in PLoS Biology, the peer-reviewed,scie...
...uppository Represents an Important Development in ...s Alternative for Effective,Insulin Delivery, Ora.../www.oramed.com ), a,developer of alternative drug...eived approval from the South Africa Medicines Con...ials on eight healthy human volunteers for ORMD,08...
Other Medicine Technology:Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 2Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology 3Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository 2Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository 3
(Date:12/4/2009).... 4 The National Cancer Institute ...t to Fred Hutchinson Cancer Research Center to bec...mation Service Contact Center. ,, The move will...rly tripling the size of its current CIS workforce...al, which is scheduled for March 15, 2010. The Sea...
(Date:12/4/2009)...-- Substantial progress has been made over the las...o diagnose and treat epilepsy and its complication...ot reached most of the 50 million people around th...n people in the United States who have the disorde...sident of the American Epilepsy Society (AES), the...
(Date:12/4/2009)...obby Berk Home & Author and Political Analyst ...oy Drive benefiting Providence Hospital’s &l...The goal is to raise $5000 in cash and toy donatio...obby Berk Home will match the donation. Toys will ... at Providence Hospital. , ...
(Date:12/4/2009)...lear enough to recommend its use, experts say , ,...ncer patients, glaucoma patients and others can be...is shows that it can help multiple sclerosis (MS) ...re the hallmark of the debilitating autoimmune dis...ids in MS appears to be comprehensive, and should ...
(Date:12/4/2009)...Calif., Dec. 4 Genomic H...the company will present results from five studies...osium (SABCS), taking place December 9-13, 2009, a...f the studies analyze Onco type DX®, the com...currently use to predict the likelihood of chemoth...
Breaking Medicine News(10 mins):Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 2Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 4Health News:Bobby Berk Home and Leslie Sanchez Announce 1st Annual Toy Drive for DC's Neediest Families 2Health News:Review Finds Marijuana May Help MS Patients 2Health News:Review Finds Marijuana May Help MS Patients 3Health News:Genomic Health to Present Five New Studies at 32nd Annual San Antonio Breast Cancer Symposium 2Health News:Genomic Health to Present Five New Studies at 32nd Annual San Antonio Breast Cancer Symposium 3Health News:Genomic Health to Present Five New Studies at 32nd Annual San Antonio Breast Cancer Symposium 4
...reWorks Makes Fast 50 List Three Years Running and...venue Growth, ATLANTA, Sept. 28 For the third ye...ding Managed Security Services,Providers (MSSP), h...ue growth from 2002-2006 and has ranked in the top...
...ZEMAN, Mont. -- Stable flies are the latest suspec...hs of hundreds of pelican chicks at the Medicine L... West Nile virus killed 800 to 1,000 pelican chick...rsity said earlier this year that he considered th...
...0-mile fundraising journey nearing completion, SA...ter,60, will triumphantly finish a five-month 2,20...ge at 4:45 p.m. Saturday, Oct. 6, in San Francisco...lly disabled son, Nathan, for nearly 19 years. Am...
... that helps them appreciate another,s discomfort s...ay News) -- Doctors are able to switch off the par...in patients experience during treatment, and inste... on patients while treating them, doctors have to ...
...AGO, Sept. 28 U.S. Environmental,Protection Agenc...rict 64,that follow-up sampling done at the Carpen...ber shows no PCB risk to students, faculty or staf...mples were taken as a precaution because PCBs were...
...viduals and Families can immediately download a fr...he cost of common prescription drugs, WHEATON, Il...cated in,Wheaton, Illinois today announced the lau...ing free personalized,prescription drug discount c...
Other Medicine News:Health News:SecureWorks Ranked 6th in Deloitte's Technology Fast 50 Program for Georgia 2Health News:SecureWorks Ranked 6th in Deloitte's Technology Fast 50 Program for Georgia 3Health News:SecureWorks Ranked 6th in Deloitte's Technology Fast 50 Program for Georgia 4Health News:Montana State University researchers investigate new suspect in West Nile deaths of pelicans 2Health News:Man Walking to California for Son Approaching Finish Line 2Health News:Brain 'Switch' Helps Doctors Deal With Patients' Pain 2Health News:EPA Says Follow-Up Sampling Shows No PCB Risk at Park Ridge Elementary School 2Health News:Free Prescription Drug Program Uses Internet to Deliver Cards - Offers Assistance to Uninsured 2
ECTRA II System without Endoscope
AZTEC Shoulder Holder and MITT
Teardrop punch, Right
Meniscus Screw
Medicine Products: